Assessment of Clinical Response to JAK Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation

This case series evaluates the clinical response to the Janus kinase inhibitor baricitinib in 3 individuals with familial chilblain lupus and assesses the effect of cold on fibroblasts.

Source: JAMA Dermatology - January 23, 2019 Category: Dermatology Source Type: research